Dr Lal Path Labs shares surged after a strong Q1FY27 earnings beat, driven by higher realisations and price hikes. Brokerages including Nomura, Nuvama and JM Financial raised target prices, citing robust growth outlook, network expansion and improving margins, with continued momentum expected from diagnostics demand and strategic investments.
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.